200. Real-World Experience with Dalbavancin for Complicated Gram-Positive Infections: A Multicenter Evaluation

BACKGROUND: Dalbavancin (DAL) received Food and Drug Administration (FDA) approval for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by Gram-positive organisms including Methicillin-resistant Staphylococcus aureus (MRSA). Due to its unique activity and dosing sc...

Descripción completa

Detalles Bibliográficos
Autores principales: Alosaimy, Sara, Pearson, Jeffrey, Veve, Michael, Dionne, Brandon, Aleissa, Muneerah, Jorgensen, Sarah C J, Rybak, Michael J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809837/
http://dx.doi.org/10.1093/ofid/ofz360.275

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809837/
http://dx.doi.org/10.1093/ofid/ofz360.275

Ejemplares similares